Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTC:RLMDD
- CUSIP: N/A
- Web: www.relmada.com
- Market Cap: $9.03 million
- Outstanding Shares: 11,999,000
- 50 Day Moving Avg: $3.11
- 200 Day Moving Avg: $5.64
- 52 Week Range: $11,999,000.00 - $2.00
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Return on Equity: -158.76%
- Return on Assets: -111.66%
- Current Ratio: 2.66%
- Quick Ratio: 2.66%
Frequently Asked Questions for Relmada Therapeutics (OTC:RLMDD)
What is Relmada Therapeutics' stock symbol?
Relmada Therapeutics trades on the OTC under the ticker symbol "RLMDD."
Who are some of Relmada Therapeutics' key competitors?
Some companies that are related to Relmada Therapeutics include Onconova Therapeutics (ONTX), Senestech (SNES), Trimel Pharmaceuticals Corp. (TRLPF), Neuralstem (CUR), Kitov Pharmaceuticals Holdings (KTOV), Transgenomic (PRPO), Anthera Pharmaceuticals (ANTH), OpGen (OPGN), Novogen Limited (NVGN), Dextera Surgical (DXTR), Galena Biopharma (GALE), Cytori Therapeutics (CYTX), CRITICAL OUTCOME T COM NPV(POST REV SPLIT) (COTQF), Celsion Corporation (CLSN), Immune Pharmaceuticals (IMNP), Lombard Medical (EVAR), RXi Pharmaceuticals Corporation (RXII) and DelMar Pharmaceuticals (DMPI).
How do I buy Relmada Therapeutics stock?
Shares of Relmada Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Relmada Therapeutics' stock price today?
MarketBeat Community Rating for Relmada Therapeutics (OTC RLMDD)MarketBeat's community ratings are surveys of what our community members think about Relmada Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Relmada Therapeutics stock can currently be purchased for approximately $4.72.
Consensus Ratings for Relmada Therapeutics (OTC:RLMDD) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Relmada Therapeutics (OTC:RLMDD)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Relmada Therapeutics (OTC:RLMDD)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Relmada Therapeutics (OTC:RLMDD)
2017 EPS Consensus Estimate: ($0.70)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Relmada Therapeutics (OTC:RLMDD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Relmada Therapeutics (OTC:RLMDD)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Relmada Therapeutics (OTC:RLMDD)
Latest Headlines for Relmada Therapeutics (OTC:RLMDD)
No headlines for this company have been tracked by MarketBeat.com